Company news
Bergs Securities recruits Jonathan Hedin to its Corporate Finance team
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue
Corporate Finance
Bergs Securities acted as sole manager and bookrunner to Modus Therapeutics Holding AB in its oversubscribed SEK 28 million rights issue.
Modus Therapeutics Holding AB is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis/septic shock and other disorders with severe systemic inflammation such as severe malaria, as well as states of anemia, related to chronic inflammation such as kidney disease.
Related News
Certified Adviser
Bergs Securities is proud to have acted as certified adviser and financial advisor to AIRA in its application to list its shares on Nasdaq First North Growth Market.
Corporate Finance
Bergs Securities acted as financial adviser and sole bookrunner to Medclair in its SEK 23 million directed share issue to Eiffel Investment Group